Dr. Jeffrey Goldberg: Chair of the Department of Ophthalmology at Stanford University School of Medicine, a practicing clinician (MD) and laboratory scientist (PhD) researching cures for glaucoma, retinitis pigmentosa, and macular degeneration. A world leader in developing methods to reverse blindness.
What this episode covers
Andrew Huberman interviews Dr. Jeffrey Goldberg for a deep dive on visual and eye health across the lifespan. They cover eye exams from newborns to seniors, how outdoor light may prevent childhood myopia, the trade-offs of corrective lenses, contact lens safety, LASIK, dry eye, and UV protection. The back half addresses the major causes of vision loss worldwide (refractive error, cataract, glaucoma, macular degeneration, diabetic retinopathy) and how to detect and slow them. They close on emerging therapies including red-light photobiomodulation, vitamin B3/NAD for glaucoma, the AREDS2 supplement formula, and using retinal imaging to detect Alzheimer's and other neurodegenerative diseases.
Also referenced (named, not recommended)
Johnson's No More Tears Baby Shampoo
Johnson & Johnson
“you can also just use like a No More Tears baby shampoo just pump a little bit into the palm of your hand once or twice a day”— Jeffrey Goldberg
Transitions Lenses
Transitions Optical
“they make glasses by the way that actually react to UV light they're called transitions there maybe a few different brands”— Jeffrey Goldberg
AREDS2 Supplement Formula
National Eye Institute
“it was very strong clinical trial support for taking what we now use this arids 2 supplementation and I'm sure we can list the formula”— Jeffrey Goldberg
Botox
AbbVie
“Botox is a treatment that you know people use for cosmetic reducing of wrinkles for example but a really good medical use of Botox is preventing that Leos spasm”— Jeffrey Goldberg
Big reveals from this episode
- Goldberg says amblyopia (lazy eye) can be corrected even into the young teens, not just before age 3-9 as previously taught.
- Recent studies point to outdoor light exposure, not just near work, as the key factor in preventing childhood myopia.
- Goldberg's clear advice: don't ration reading glasses to 'exercise' your eyes; just wear the correction that gives you the best vision.
- Athletes train with strobe goggles that black out vision a fraction of each second to push from normal to 'supernormal' vision.
- Lowering eye pressure slows glaucoma even in patients whose pressure is already in the normal range.
- Red and near-infrared light therapy shows compelling early evidence for slowing age-related macular degeneration.
- The AREDS2 supplement formula reduced progression of moderate-to-severe dry macular degeneration by about 25%.
- Retinal imaging may become a leading diagnostic tool for predicting and tracking Alzheimer's and other neurodegeneration.
Worth remembering
- Every newborn should get a 'red reflex' check; absence of it can signal retinoblastoma, the most common pediatric eye cancer.
- Animal studies show that limiting vision to close range lengthens the eyeball, producing myopia (nearsightedness).
- The surface of the eye is largely self-cleaning; tears contain enzymes that break down bacteria and their toxins.
- Presbyopia translates to 'disease vision of the aged'; the eye's lens stiffens with age, maxing out reading correction around plus 2.5 to 3.
- 20/20 vision means reading at 20 feet what an average healthy person reads at 20 feet; hawks and owls can have ~20/10 to 20/8 vision.
- Car windshields filter UV light, which is why UV-reactive 'transitions' lenses don't darken inside a car.
- When reading or staring at screens, people blink less, which worsens dry eye by spreading tears and oils less effectively.
- Eye pressure follows a circadian rhythm, peaking at night during sleep, which may explain some normal-pressure glaucoma.
- In the AREDS trial, beta-carotene was linked to slightly increased cancer risk, mostly in smokers, and was removed in AREDS2.
- High-dose vitamin B3 (nicotinamide), which feeds the NAD pathway, is an active hot area of phase-three glaucoma trials.